文献速递外周动脉疾病

支架移植物与药物涂层球囊在复杂股腘动脉病变腔内治疗中的对比:两中心经验

Stent Graft vs Drug-Coated Balloon in Endovascular Treatment of Complex Femoropopliteal Artery Lesions: A 2-Center Experience.
PubMed 文献 · J Endovasc Ther · 2023-09-20

该两中心回顾性研究纳入150例患者161条肢体,比较Viabahn支架移植物与药物涂层球囊治疗TASC C/D股腘动脉病变的疗效。支架移植物组12个月和24个月一期通畅率均显著高于药物涂层球囊组。两组临床驱动靶病变血运重建、死亡率和重大截肢率无显著差异。

要点

  • 支架移植物组12个月一期通畅率75.8% vs 药物涂层球囊组39.2%(p=0.02)。
  • 支架移植物组24个月一期通畅率64.1% vs 药物涂层球囊组31.9%(p=0.02)。
  • 两组临床驱动靶病变血运重建、死亡率和重大截肢率无显著差异。

核心结论

  • 在复杂长段股腘动脉病变中,支架移植物与药物涂层球囊相比与显著更高的一期通畅率相关。
  • 两组临床驱动靶病变血运重建豁免率和重大截肢率无显著差异。
  • 作者认为严格遵循支架移植物使用标准很重要,以避免早期再狭窄导致急性血栓形成和严重肢体缺血。
  • 作者建议对接受支架移植物植入的患者进行更密切的监测。
  • 作者认为需要开展比较支架移植物与药物涂层球囊的随机对照试验。

研究设计与样本

  • 2013年7月至2019年5月在两医疗中心开展的回顾性研究,比较Viabahn支架移植物与药物涂层球囊血管成形术治疗TASC C/D股腘动脉病变的临床结局。
  • 研究采用重叠权重法调整基线特征差异,以减少两组间混杂因素和选择偏倚的影响。
  • 共纳入150例患者161条肢体,其中Viabahn支架移植物组67条肢体(65例患者),药物涂层球囊组94条肢体(85例患者)。
  • 主要终点为24个月一期通畅率,次要终点包括临床驱动靶病变血运重建豁免率、全因死亡率和重大截肢率。

主要发现

  • 药物涂层球囊组中22条靶血管(23.4%)在药物涂层球囊血管成形术前接受了定向斑块旋切术,37条靶血管(39.4%)因早期回缩或严重夹层接受了补救性裸金属支架植入。
  • 支架移植物组12个月一期通畅率为75.8%,药物涂层球囊组为39.2%(p=0.02)。
  • 支架移植物组24个月一期通畅率为64.1%,药物涂层球囊组为31.9%(p=0.02)。
  • 两组在临床驱动靶病变血运重建、死亡率和重大截肢率方面无显著差异。
  • 多因素分析显示,药物涂层球囊血管成形术是与再狭窄相关的唯一独立预测因子(风险比[HR]=0.264,95%置信区间[CI]=0.100-0.696,p=0.007)。

关键数值与推荐

  • 支架移植物组12个月一期通畅率75.8% vs 药物涂层球囊组39.2%(p=0.02)。
  • 支架移植物组24个月一期通畅率64.1% vs 药物涂层球囊组31.9%(p=0.02)。
  • 药物涂层球囊血管成形术与再狭窄独立相关(HR=0.264,95%CI=0.100-0.696,p=0.007)。

临床怎么用

  • 作者认为严格遵循支架移植物使用标准很重要,以避免早期再狭窄导致急性血栓形成和严重肢体缺血。
  • 作者建议对接受支架移植物植入的患者进行更密切的监测。
  • 作者认为需要开展比较支架移植物与药物涂层球囊的随机对照试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Both stent grafts (SG) and drug-coated balloons (DCBs) have shown to be effective treatments for long and complex femoropopliteal (FP) lesions. However, there has not been a clinical trial comparing the 2 treatments directly. This study aims to compare the primary patency (PP) and clinical outcomes of SG and DCB for endovascular treatment of complex FP Trans-Atlantic Inter-Society Consensus (TASC) C/D lesions in patients. METHODS: From July 2013 to May 2019, a retrospective study was conducted at 2 medical centers to compare the clinical outcomes of Viabahn SG and DCB angioplasty in patients with TASC C/D FP lesions. The study used overlap weighting to adjust for differences in baseline characteristics and to reduce the impact of confounding factors and selection bias between the 2 groups. The primary endpoint was PP through 24 months, and the secondary endpoints included freedom from clinical-driven target lesion revascularization (CD-TLR), all-cause of death rate, and major amputation rate. RESULTS: A total of 161 limbs in 150 patients with TASC C/D FP lesions were treated either with Viabahn SGs (67 limbs, 65 patients) or DCBs (94 limbs, 85 patients). In the DCB group, 22 target vessels (23.4%) underwent directional atherectomy before DCB angioplasty and 37 target vessels (39.4%) underwent bail-out bare-metal stent implantation for early recoil or severe dissection. The SG group had significantly higher PP rates at both the 12 and 24 months than in the DCB group (75.8% vs 39.2%, p=0.02; 64.1% vs 31.9%, p=0.02), respectively. However, there were no significant differences between the 2 groups in terms of CD-TLR, death rate, and major amputation rate. According to the results of multivariate analysis, DCB angioplasty was the only independent predictor associated with restenosis (hazard ratio [HR]=0.264, 95% confidence interval [CI]=0.100-0.696, p=0.007). CONCLUSIONS: This study showed that SG was associated with a significantly higher PP rate in complex long FP lesions compared with DCB angioplasty. However, there was no significant difference in the freedom from CD-TLR and major amputation rate. It is important to follow the criteria for using SG strictly to avoid early restenosis, which can lead to acute thrombosis and severe limb ischemia. Closer monitoring is recommended for patients who undergo SG implantation.Clinical ImpactThere has no head-to-head clinical trial that compares DCB and SG in complex long FP lesions. This study showed that SG following the criteria was associated with a significantly higher PP rate compared with DCB angioplasty. Closer monitoring is recommended for patients with SG to avoid acute thrombosis. Randomized controlled trials comparing SG and DCB are necessary.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Ye M, Ni Q, Zhu Y, et al. Stent Graft vs Drug-Coated Balloon in Endovascular Treatment of Complex Femoropopliteal Artery Lesions: A 2-Center Experience. J Endovasc Ther. 2023. PMID: 37728023. doi:10.1177/15266028231201097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。